Literature DB >> 6456083

Antitumor activity of 3',5'-diesters of 5-fluoro-2'-deoxyuridine against murine leukemia L1210 cells.

F Kanzawa, A Hoshi, K Kuretani, M Saneyoshi, T Kawaguchi.   

Abstract

Antitumor activity of several 3',5'-diesters of 5-fluoro-2'-deoxyuridine (FUdR) against L1210 leukemia cells following intraperitoneal administration was examined. Esters of FUdR with aromatic acid or aliphatic acid of longer chain length were markedly active. Their activities, with respect to ILS30, were as much as 100 times that of unesterified FUdR. 3',5'-ditoluoyl FUdR also had an improved therapeutic effect: its therapeutic ratio was increased to 8.1, as against 2.0 for FUdR. On the other hand, 3',5'-diesters of FUdR with aliphatic acid of shorter chain length do not appear to be as active as FUdR. The relationship between the antitumor activity and plasma levels has also been examined. After 3',5'-diacetyl FUdR, which is one of the drug group showing low cytotoxicity, the plasma concentration rapidly decreased to an unmeasurable level 3 h after dosing. This tendency is similar to that shown in FUdR. On the other hand, with 3',5'-dipalmitoyl FUdR and 3',5'-dibenzoyl FUdR, each of which has a marked antitumor effect, plasma concentrations decreased slowly and were maintained for as long as 48 h after dosing. The results show that the cytotoxicity of diesters of FUdR is correlated with the duration of a high plasma level of FUdR.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456083     DOI: 10.1007/bf00253005

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  STUDIES OF FLUORINATED PYRIMIDINES. XVIII. THE DEGRADATION OF 5-FLUORO-2'-DEOXYURIDINE AND RELATED COMPOUNDS BY NUCLEOSIDE PHOSPHORYLASE.

Authors:  G D BIRNIE; H KROEGER; C HEIDELBERGER
Journal:  Biochemistry       Date:  1963 May-Jun       Impact factor: 3.162

2.  Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2'-deoxyuridine on transplanted tumors.

Authors:  C HEIDELBERGER; L GRIESBACH; O CRUZ; R J SCHNITZER; E GRUNBERG
Journal:  Proc Soc Exp Biol Med       Date:  1958-02

Review 3.  Fluorinated pyrimidines.

Authors:  C Heidelberger
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1965

4.  Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver.

Authors:  J H Burrows; R W Talley; E H Drake; W G Tucker
Journal:  Cancer       Date:  1967-11       Impact factor: 6.860

5.  The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.

Authors:  M Chadwick; W I Rogers
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

6.  Fluorinated pyrimidines. 34. Structure-activity studies of methylated 5-fluoro-2'-deoxyuridine derivatives.

Authors:  R J Kent; T A Khwaja; C Heidelberger
Journal:  J Med Chem       Date:  1970-01       Impact factor: 7.446

Review 7.  On the nature of thymineless death.

Authors:  S S Cohen
Journal:  Ann N Y Acad Sci       Date:  1971-11-30       Impact factor: 5.691

8.  Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil.

Authors:  P Langen; G Etzold; D Bärwolff; B Preussel
Journal:  Biochem Pharmacol       Date:  1967-09-09       Impact factor: 5.858

9.  Determinants of 5-fluorouracil sensitivity in human tumors.

Authors:  R G Moran; C Heidelberger
Journal:  Bull Cancer       Date:  1979       Impact factor: 1.276

10.  Antitumor activity of alkylesters of 1-beta-D-ribofuranosyl-5-fluorouracil-5'-phosphate against murine lymphoma L5178Y resistant to 1-beta-D-ribofuranosyl-5-fluorouracil.

Authors:  F Kanzawa; A Hoshi; K Kuretani
Journal:  Bull Cancer       Date:  1979       Impact factor: 1.276

View more
  4 in total

1.  Nonenzymatic and enzymatic hydrolysis of 5-fluoro-2'-deoxyuridine (FUdR) esters.

Authors:  T Kawaguchi; S Fukushima; Y Hayashi; M Nakano
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

2.  Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.

Authors:  Christopher P Landowski; Xueqin Song; Philip L Lorenzi; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.

Authors:  F Kanzawa; K Nishio; T Ishida; M Fukuda; H Kurokawa; H Fukumoto; Y Nomoto; K Fukuoka; K Bojanowski; N Saijo
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Competitive binding radioassay for the determination of 5-fluorodeoxyuridine and 5-fluorodeoxyuridine-5'-monophosphate levels in plasma and tumor tissue.

Authors:  S Miyata; H Mikami; M Tai; T Hori; H Fujita
Journal:  Jpn J Cancer Res       Date:  1991-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.